Medical journal’s editorial on Vioxx evidence may bolster plaintiff cases
Medical journal’s editorial on Vioxx evidence may bolster plaintiff cases
TimesLeader.com - Dec 11 2:28 PM
NEW YORK - Merck & Co.’s failure to disclose information about additional heart attacks in a Vioxx clinical trial to a prominent medical journal strengthens plaintiffs’ cases because it bolsters claims that the company deliberately disguised the pain reliever’s risks, experts said.Save to My Web
Vioxx Editorial May Bolster Merck Suits
Newsday.com - Dec 12 7:25 AM
NEW YORK — Merck & Co.’s failure to disclose information about additional heart attacks in a Vioxx clinical trial to a prominent medical journal strengthens plaintiffs’ cases because it bolsters claims that the company deliberately disguised the pain reliever’s risks, experts said.Save to My Web
Merck Faces Lawyer Who Beat Them Before in Next Vioxx Trial
Bloomberg.com - Dec 12 9:39 PM
Dec. 13 (Bloomberg) — Merck & Co., after one win, one loss and one mistrial in defending lawsuits over its Vioxx painkiller, will next face the lawyer who beat the company and the first victim who used the drug long enough to risk a heart attack.Save to My Web
Vioxx Editorial May Bolster Merck Suits
Newsday.com - Dec 12 8:51 AM
NEW YORK — Merck & Co.’s failure to disclose information about additional heart attacks in a Vioxx clinical trial to a prominent medical journal strengthens plaintiffs’ cases because it bolsters claims that the company deliberately disguised the pain reliever’s risks, experts said.Save to My Web
Vioxx Editorial May Bolster Merck Suits
San Francisco Chronicle - Dec 12 7:25 AM
Merck & Co.’s failure to disclose information about additional heart attacks in a Vioxx clinical trial to a prominent medical journal strengthens plaintiffs’ cases because it bolsters claims that the company deliberately disguised the pain reliever’s risks, experts said.Save to My Web
(AFX UK Focus) 2005-12-09 22:06 GMT: Merck shares drop after journal questions Vioxx study - UPDATE 5
Interactive Investor - Dec 09 2:34 PM
BOSTON (AFX) — News that the prestigious New England Journal of Medicine has accused Merck of manipulating data from a 2000 Vioxx study weighed on the drugmaker’s stock Friday.Save to My Web
Vioxx Editorial May Bolster Merck Suits
New York Newsday - Dec 11 7:25 AM
Merck & Co.’s failure to disclose information about additional heart attacks in a Vioxx clinical trial to a prominent medical journal strengthens plaintiffs’ cases because it bolsters claims that the company deliberately disguised the pain reliever’s risks, experts said.Save to My Web